Zacks Investment Research upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a sell rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “
Several other equities analysts have also recently commented on the stock. Leerink Swann boosted their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the company an outperform rating in a research report on Thursday, February 8th. Cowen restated a buy rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 10th. BidaskClub upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a research report on Monday, January 15th. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the company a buy rating in a research report on Wednesday, February 7th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a sell rating to a hold rating in a research report on Friday, February 2nd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Amicus Therapeutics has an average rating of Buy and an average price target of $19.06.
Amicus Therapeutics (NASDAQ:FOLD) opened at $14.49 on Tuesday. The company has a market cap of $2,739.83, a P/E ratio of -7.92 and a beta of 1.60. The company has a quick ratio of 5.53, a current ratio of 5.60 and a debt-to-equity ratio of 0.47. Amicus Therapeutics has a 12-month low of $6.41 and a 12-month high of $17.40.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.11). The firm had revenue of $14.73 million during the quarter, compared to analyst estimates of $14.50 million. Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. sell-side analysts predict that Amicus Therapeutics will post -1.26 earnings per share for the current fiscal year.
In related news, insider Jay Barth sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $15.05, for a total transaction of $75,250.00. Following the completion of the transaction, the insider now directly owns 90,409 shares in the company, valued at approximately $1,360,655.45. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Daphne Quimi sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total transaction of $117,760.00. Following the transaction, the senior vice president now owns 62,676 shares of the company’s stock, valued at $922,590.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 207,870 shares of company stock valued at $3,066,112. 3.40% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Sage Capital Advisors llc acquired a new position in Amicus Therapeutics during the 3rd quarter worth approximately $154,000. Engineers Gate Manager LP bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $155,000. Neuberger Berman Group LLC bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $196,000. Great West Life Assurance Co. Can grew its holdings in Amicus Therapeutics by 40.2% during the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 4,145 shares during the last quarter. Finally, Sterling Capital Management LLC bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $218,000.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/21/amicus-therapeutics-fold-upgraded-by-zacks-investment-research-to-hold-2.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.